MedPath

Clinical Performance Evaluation of AMH Assay

Completed
Conditions
Anti-Mullerian Hormone
Registration Number
NCT03131388
Lead Sponsor
Beckman Coulter, Inc.
Brief Summary

The Access AMH Assay is an in vitro diagnostic assay intended as an aid for fertility assessment. The purpose of the study is to evaluate the clinical performance of the Access AMH Assay in the intended use population.

Detailed Description

same as brief summary

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
277
Inclusion Criteria
  • ≥ 21 and < 46 years of age
  • Regular menstrual cycle
  • Both ovaries present
Exclusion Criteria
  • Evidence of PCOS
  • Confirmed ovarian endometrioma
  • Ovarian surgery prior to enrollment
  • Being treated for cancer
  • Hormonal contraceptive use prior to enrollment
  • Currently pregnant

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Measurement of AMH as an aid for fertility assessmentDay 2 to 4 of menstrual cycle

Comparison of AMH levels in women at different levels of AFC to aid in assessing ovarian reserve

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (13)

CARE

🇺🇸

Dallas, Texas, United States

RAD

🇺🇸

Newark, Delaware, United States

Vios Fertility

🇺🇸

Swansea, Illinois, United States

BIVF

🇺🇸

Waltham, Massachusetts, United States

BRI

🇺🇸

Phoenix, Arizona, United States

FSMG

🇺🇸

San Diego, California, United States

WRMG

🇺🇸

Clearwater, Florida, United States

Stanford

🇺🇸

Palo Alto, California, United States

PNWF

🇺🇸

Seattle, Washington, United States

Clinique Ovo

🇨🇦

Montreal, Quebec, Canada

Mainline Fertility

🇺🇸

Bryn Mawr, Pennsylvania, United States

Univ Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

CORM

🇺🇸

Webster, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath